Assay.Works

Assay.Works is a private contract research organization (CRO) occupying a 750 m2 state-of-the-art laboratory located in the Regensburg BioPark, the second largest hub of the Bavarian biotech cluster. Our mission is to accelerate our partner’s research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.

Recent Publications

• Fan F, Hu R, Munzli A, Chen Y, Dunn RT 2nd, Weikl K, Strauch S, Schwandner R, Afshari CA, Hamadeh H, Nioi P. Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. Toxicol Sci. 2015 Jun;145(2):283-95. doi: 10.1093/toxsci/kfv052. Epub 2015 Mar 9
  
• Xiong Y, Swaminath G, Cao Q, Yang L, Guo Q, Salomonis H, Lu J, Houze JB, Dransfield PJ, Wang Y, Liu JJ, Wong S, Schwandner R, Steger F, Baribault H, Liu L, Coberly S, Miao L, Zhang J, Lin DC, Schwarz M. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol. 2013 Apr 30;369(1-2):119-29. doi: 10.1016/j.mce.2013.01.009. Epub 2013 Feb 9.
  
• Yu V, Fisch T, Long AM, Tang J, Lee JH, Hierl M, Chen H, Yakowec P, Schwandner R, Emkey R. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases. 2012. J Biomol Screen. Jan;17(1):27-38.
  
• Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, Quon K, Kassner PD, Ruefli-Brasse AA, Watson VJ, Fajardo F, Jackson A, Zondlo J, Sun Y, Ellison AR, Plewa CA, San MT, Robinson J, McCarter J, Schwandner R, Judd T, Carnahan J, Dussault I. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. 2011. Cancer Res. Sep 1;71(17):5818-26.
  
• Lee T., Schwandner R., Swaminath G., Weiszmann J., Cardozo M., Greenberg J., Jaeckel P., Ge H., Wang Y., Jiao X., Liu J., Kayser F., Tian H., Li Y. 2008. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol. Dec;74(6):1599-609.
  
• Beck HP., Kohn T., Rubenstein S., Hedberg C., Schwandner R., Hasslinger K., Dai K., Li C., Liang L., Wesche H., Frank B., An S., Wickramasinghe D., Jaen J., Medina J., Hungate R., Shen W. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. 2008. Bioorg Med Chem Lett. Feb 1;18(3):1037-41.